Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | GRB2 | P62993 | 1/20 | 0.56 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.55 |
| ▸ | MIF | P14174 | 8/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002655 | 1.00 | POLB (0.57) | POLBAKR1B1LCKFYNGRB2 | |
| SCHEMBL9436016 | 0.85 | KDM4E (0.54) | POLBAKR1B1HSD17B3MIFKDM4E | |
| SCHEMBL11128154 | 0.83 | NPC1 (0.55) | HSD17B3MIFMEN1KMT2AMAPT | |
| SCHEMBL29066603 | 0.82 | ESR2 (0.61) | POLBAKR1B1HSD17B3MIFKDM4E | |
| SCHEMBL220708 | 0.82 | HSD17B3 (0.65) | POLBAKR1B1HSD17B3MIFKDM4E | |
| SCHEMBL30405545 | 0.82 | HSD17B3 (0.65) | POLBAKR1B1HSD17B3MIFKDM4E | |
| SCHEMBL10845026 | 0.82 | CA12 (0.50) | POLBAKR1B1MIFKDM4EMEN1 | |
| SCHEMBL6037595 | 0.81 | POLB (0.59) | POLBAKR1B1HSD17B3MIFKDM4E | |
| SCHEMBL2403666 | 0.81 | RAB9A (0.59) | POLBAKR1B1KDM4EMEN1KMT2A | |
| SCHEMBL28164061 | 0.81 | POLB (0.59) | POLBAKR1B1HSD17B3MIFKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113717187-A | Fluorescent probe for revealing endoplasmic reticulum repair mechanism by using fluorescence lifetime imaging, and preparation method and application thereof | 安徽大学 | 2021-11-30 | — | — | CN | claimed |
| EP-3937966-B1 | COMPOSITIONS AND METHODS FOR PROTECTING TYPE 2 ALVEOLAR EPITHELIAL CELLS (AEC2) | REIN THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260062444-A1 | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS | REIN THERAPEUTICS, INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-12497431-B2 | Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis | REIN THERAPEUTICS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250302910-A1 | DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250268977-A1 | COMPOSITIONS AND METHODS FOR PROTECTING TYPE 2 ALVEOLAR EPITHELIAL CELLS (AEC2) | REIN THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250262273-A1 | MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | REIN THERAPEUTICS, INC. | 2025-08-21 | — | — | US | disclosed |
| CN-112996530-B | Dry powder formulations of the pit protein-1 peptide and methods of use thereof | 得克萨斯州大学系统董事会 | 2025-06-03 | — | — | CN | disclosed |
| EP-4554605-A2 | MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF | Rein Therapeutics, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12280089-B2 | Dry powder formulation of caveolin-1 peptides and methods of use thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-22 | — | — | US | disclosed |
| US-20120225449-A1 | Method and appraratus utilizing enzyme substrates producing slow diffusing fluorescent product appearances and chromogens, and use in combination with fast diffusing product appearances | ROTH GEOFFREY N (US) | 2012-09-06 | — | — | US | disclosed |
| US-8008059-B1 | Method utilizing enzyme substrates producing insoluble fluorescent products and chromogens, and use in combination with enzyme substrates producing soluble products | MICROLOGY LABORATORIES, LLC (US) | 2011-08-30 | — | — | US | disclosed |
| CN-101481371-A | Benzo pyran derivative, and synthesis and use thereof | DELEI KONG (CN) | 2009-07-15 | — | — | CN | disclosed |
| EP-0253492-B1 | Fibre-optic probe | SHILEY INC (US) | 1994-06-01 | — | — | EP | disclosed |
| US-4956480-A | 7-amino-4-methyl-coumarin-3-carboxyalkyl derivates and fluorescent conjugates thereof | BIOCARB AB (SE) | 1990-09-11 | — | — | US | disclosed |
| EP-0277139-B1 | 7-AMINO-4-METHYL-COUMARIN-3-CARBOXYALKYL DERIVATIVES AND FLUORESCENT CONJUGATES THEREOF | BIOCARB AB (SE) | 1990-08-08 | — | — | EP | disclosed |
| US-4927222-A | Dual optical fiber device | SHILEY INCORPORATED (US) | 1990-05-22 | — | — | US | disclosed |
| EP-0313274-A1 | Enzyme assay method | KINGS COLLEGE LONDON (GB) | 1989-04-26 | — | — | EP | disclosed |
| EP-0123543-B1 | LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION AND USE AND COMPOSITIONS CONTAINING THEM | MERCK FROSST CANADA INC. (CA) | 1988-02-03 | — | — | EP | disclosed |
| EP-0253492-A2 | Fibre-optic probe | BIOMEDICAL SENSORS LTD (GB) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062444-A1 | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS | VIP, CALCA, CALCRL | POLB 4660/4885AKR1B1 4501/4885LCK 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.